Global Chronic Lymphocytic Leukemia Therapeutics Overview
Chronic lymphocytic leukemia (CLL) is a cancer which starts in cells that become certain white blood cells (called lymphocytes) in the bone marrow. It is the most common leukemia in adults, the cancer (leukemia) cells start in the bone marrow but then go into blood.
The chronic lymphocytic leukemia therapeuticsmarket is expected to show a rapid growth over the forecast period, owing to frequent launch of novel therapeutics for chronic lymphocytic leukemia treatment by key players in the market.
For instance, in March 2016, U.S. Food and Drug Administration (FDA) approved ibrutinib, an orally administered BTK inhibitor, for the first-line treatment of patients with Chronic Lymphocytic Leukemia. Janssen Biotech, Inc., an AbbVie company, and Pharmacyclics LLC has jointly developed and commercialized IMBRUVICA. .
In June 2018, AbbVie Inc. and Genentech Inc., a F. Hoffmann-La Roche AG company received U.S. Food and Drug Administration (FDA) approval for its drug Venclexta (venetoclax) in combination with Rituxan (rituximab) for the treatment of people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Venclexta is being developed by AbbVie Inc. and Genentech Inc. however; drug is jointly commercialized by companies in the U.S. and commercialized by AbbVie Inc. outside the U.S.
Furthermore, high prevalence of chronic lymphocytic leukemia is expected to robustly rise demand for its therapeutics in the market and significantly boost the market growth. As per the American Cancer Society\'s estimates in 2018 it is expected that around 20,940 new cases of chronic lymphocytic leukemia will be diagnosed in the U.S. and around 4,510 deaths will occur due to chronic lymphocytic leukemia.
The chronic lymphocytic leukemia therapeutics market has been segmented on the basis of drug type, distribution channel, and region.
On the basis of drug type, the chronic lymphocytic leukemia therapeutics market has been segmented into Idelalisib (zydelig), ofatumumab (arzerra), bendamustine hydrochloride (treanda), venetoclax (venclexta), obinutuzumab (gazyva), Ibrutinib (Imbruvica), prednisone, fludarabine (fludara), and others
On the basis of distribution channel, the chronic lymphocytic leukemia therapeutics market has been segmented in hospital, retail pharmacies, and online pharmacies.
On the basis of region, the target market has been segmented into North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. North America is expected to account major market share as compared to that of other regions.
Key players operating in the chronic lymphocytic leukemia therapeutics market includes, Abbvie Inc., Johnson & Johnson,GlaxoSmithKline Plc., Teva Pharmaceutical Industries Ltd, F. Hoffmann-La Roche Ltd, Novartis International AG, Gilead Sciences Inc., Genzyme Corporation, Genmab A/S,Biogen Idec, Celgene Corporation, AstraZeneca plc, Arno Therapeutics Inc., and others.
Global Chronic Lymphocytic Leukemia Therapeutics Table of Contents
- Research Objective and Assumption
- Research Objectives
- Assumptions
- Abbreviations
- Market Preview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Drug Type
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
- Opportunity Map Analysis
- Report Description
- Market Dynamics Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Market Trends
- Drivers- Restraints Impact Analysis
- PEST Analysis
- Porter’s Five Forces Analysis
- Market Dynamics
- Market Segmentation, By Drug Type, 2018 – 2028, (US$ Mn)
- Introduction
- Market Value and Forecast (US$ Mn), and Share Analysis (%), 2018 — 2028
- Y-o-Y Growth Analysis (%), 2019 – 2028
- Segment Trends
- 75 mg
- Introduction
- Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2018 – 2028
- 150 mg
- Introduction
- Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2018 – 2028
- 300 mg
- Introduction
- Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2018 – 2028
- Introduction
- Market Segmentation, By Distribution Channel, 2018 – 2028, (US$ Mn)
- Introduction
- Market Share Analysis, 2018 and 2026 (%)
- Y-o-Y Growth Analysis (%), 2019 – 2028
- Segment Trends
- Retail Pharmacy
- Introduction
- Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2018 – 2028
- Online Pharmacy
- Introduction
- Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2018 – 2028
- Hospital Pharmacy
- Introduction
- Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2018 – 2028
- Introduction
- Global Market, By Region, 2018 – 2028, (US$ Mn)
- Introduction
- Market Value and Forecast (US$ Mn), and Share Analysis (%), 2018 — 2028
- Y-o-Y Growth Analysis (%), 2019 – 2028
- Regional Trends
- North America
- Market Size and Forecast (US$ Mn), By Drug Type, 2018 – 2028
- Market Size and Forecast (US$ Mn), By Distribution Channel, 2018 – 2028
- Market Size and Forecast (US$ Mn), By Country, 2018 – 2028
- Introduction
Ø U.S.
Ø Canada
- Latin America
- Market Size and Forecast (US$ Mn), By Drug Type, 2018 – 2028
- Market Size and Forecast (US$ Mn), By Distribution Channel, 2018 – 2028
- Market Size and Forecast (US$ Mn), By Country, 2018 – 2028
Ø Brazil
Ø Mexico
Ø Argentina and Chile
Ø Rest of Latin America
Ø Europe
- Market Size and Forecast (US$ Mn), By Drug Type, 2018 – 2028
- Market Size and Forecast (US$ Mn), By Distribution Channel, 2018 – 2028
- Market Size and Forecast (US$ Mn), By Country, 2018 – 2028
Ø Germany
Ø UK
Ø France
Ø Russia
Ø Italy
Ø Switzerland
Ø Sweden
Ø Rest of Europe
- Asia Pacific
- Market Size and Forecast (US$ Mn), By Drug Type, 2018 – 2028
- Market Size and Forecast (US$ Mn), By Distribution Channel, 2018 – 2028
- Market Size and Forecast (US$ Mn), By Country, 2018 – 2028
Ø China
Ø India
Ø Australia & New Zealand
Ø Japan
Ø South Korea
Ø Rest of Asia Pacific
- Middle East
- Market Size and Forecast (US$ Mn), By Drug Type, 2018 – 2028
- Market Size and Forecast (US$ Mn), By Distribution Channel, 2018 – 2028
- Market Size and Forecast (US$ Mn), By Country, 2018 – 2028
Ø GCC
Ø Israel
Ø Saudi Arabia
Ø UAE
Ø Rest of Middle East
- Africa
- Market Size and Forecast (US$ Mn), By Drug Type, 2018 – 2028
- Market Size and Forecast (US$ Mn), By Distribution Channel, 2018 – 2028
- Market Size and Forecast (US$ Mn), By Country, 2018 – 2028
Ø North Africa
Ø Central Africa
Ø South Africa
- Competitive Landscape
- Heat Map Analysis
- Company Profiles
- Abbvie Inc.
Ø Company Overview
Ø Product Portfolio
Ø Key Highlights
Ø Financial Overview
Ø Business Strategy Overview
- Johnson & Johnson
Ø Company Overview
Ø Product Portfolio
Ø Key Highlights
Ø Financial Overview
Ø Business Strategy Overview
- GlaxoSmithKline plc
Ø Company Overview
Ø Product Portfolio
Ø Key Highlights
Ø Financial Overview
Ø Business Strategy Overview
§ Teva Pharmaceutical Industries Ltd
Ø Company Overview
Ø Product Portfolio
Ø Key Highlights
Ø Financial Overview
Ø Business Strategy Overview
- F. Hoffmann-La Roche Ltd
Ø Company Overview
Ø Product Portfolio
Ø Key Highlights
Ø Financial Overview
Ø Business Strategy Overview
- Novartis International AG
Ø Company Overview
Ø Product Portfolio
Ø Key Highlights
Ø Financial Overview
Ø Business Strategy Overview
- Gilead Sciences Inc.
Ø Company Overview
Ø Product Portfolio
Ø Key Highlights
Ø Financial Overview
Ø Business Strategy Overview
- Genzyme Corporation
Ø Company Overview
Ø Product Portfolio
Ø Key Highlights
Ø Financial Overview
Ø Business Strategy Overview
- Genmab A/S
- Company Overview
- Product Portfolio
Ø Key Highlights
Ø Financial Overview
Ø Business Strategy Overview
- Biogen Idec
Ø Company Overview
Ø Product Portfolio
Ø Key Highlights
Ø Financial Overview
Ø Business Strategy Overview
- Celgene Corporation
Ø Company Overview
Ø Product Portfolio
Ø Key Highlights
Ø Financial Overview
Ø Business Strategy Overview
- AstraZeneca plc
Ø Company Overview
Ø Product Portfolio
Ø Key Highlights
Ø Financial Overview
Ø Business Strategy Overview
- Arno Therapeutics Inc.
Ø Company Overview
Ø Product Portfolio
Ø Key Highlights
Ø Financial Overview
Ø Business Strategy Overview
- Analyst Views
- Section
- Research Methodology
- About Us
- Contact
FAQs
The chronic lymphocytic leukemia therapeutics market has been segmented on the basis of drug type, distribution channel, and region.
Key players operating in the chronic lymphocytic leukemia therapeutics market includes, Abbvie Inc., Johnson & Johnson,GlaxoSmithKline Plc., Teva Pharmaceutical Industries Ltd, F. Hoffmann-La Roche Ltd, Novartis International AG, Gilead Sciences Inc., Genzyme Corporation, Genmab A/S,Biogen Idec, Celgene Corporation, AstraZeneca plc, Arno Therapeutics Inc., and others..
High cost of treatment might hamper the market.
High prevalence of chronic lymphocytic leukemia is expected to robustly rise demand for its therapeutics in the market and significantly boost the market growth.
North America is expected to account major market share as compared to that of other regions.